Skip to content
Peptigraph home

Tirzepatide for Bone Health: What the Evidence Shows

What human and animal studies show about Tirzepatide for bone health, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP dual agonistUpdated
Strongest evidence
Human observational
Human studies
15
PubMed records, our ledger
Animal studies
0
PubMed records, our ledger
Studies we summarised
1
with an outcome for bone health

Evidence for bone health

Each row is an outcome related to bone health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Tirzepatide for bone health: outcomes in published studies
OutcomeResultStudy typeSource
Osteoporosis or fragility fractureTirzepatide was associated with a higher risk of osteoporosis or fragility fracture than other GLP-1 RAs (hazard ratio 1.44, 95% CI 1.22-1.69); observational, association only.Human observationaln = 459886Diabetes research and clinical practice 2025, PMID 41218687

PubMed records for Tirzepatide and bone health: 15 human, 0 animal (search counts, not studies we reviewed). Grades follow our evidence scale.

How strong is it?

Strongest evidence:Human observational evidence, 3 of 4Diabetes research and clinical practice 2025, PMID 41218687

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Other peptides people research for bone health

No other peptide in our index has a bone health page yet.

Common questions

Does Tirzepatide help with bone health?

The strongest study we summarise for bone health is human observational evidence, across 1 study with an outcome for bone health. That is not proof it works in people.

Is Tirzepatide approved for bone health?

Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.

More on Tirzepatide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.Diabetes research and clinical practice · 2025PMID 41218687Accessed 2 Oct 2026

Found an error? Report a correction.